Athersys, Inc (ATHX)

Etorro trading 970x250
Athersys, Inc (ATHX) Logo

About Athersys, Inc

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Phase II clinical study for the treatment of patients with acute myocardial infarction, and has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio. Address: 3201 Carnegie Avenue, Cleveland, OH, United States, 44115-2634

Athersys, Inc News and around…

Latest news about Athersys, Inc (ATHX) common stock and company :

Athersys plans to sell $12 million in securities to raise cash for operations
15 Aug, 2022 Yahoo! Finance

Athersys Inc., the Cleveland-based regenerative medicine company, could raise up to $12 million by selling its shares and warrants to "a single healthcare-focused U.S. institutional investor." The unnamed institutional investor has agreed to acquire up to 48 million shares of Athersys stock, stock equivalents and warrants for 25 cents apiece in a deal expected to close by Aug. 17, the Cleveland company said in a Monday statement. Athersys, which is in the midst of a financial and operational restructuring, said it would use net proceeds from the sales "for general corporate purposes."

Athersys, Inc. Announces $12 Million Registered Direct Offering
15 Aug, 2022 FinancialContent

Athersys, Inc. (Nasdaq: ATHX) today announced that it has entered into a definitive agreement with a single healthcare-focused U.S. institutional investor for the purchase and sale of 48,000,000 shares of the Company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 48,000,000 shares of common stock at a purchase price per share (and accompanying warrant) of $0.25 in a registered direct offering. The warrants will have an exercise price of $0.2554 per share, will be initially exercisable beginning six months following the date of issuance and will expire five years from the initial exercise date.

News Flash: One Analyst Just Made An Incredible Upgrade To Their Athersys, Inc. (NASDAQ:ATHX) Forecasts
14 Aug, 2022 Yahoo! Finance

Shareholders in Athersys, Inc. ( NASDAQ:ATHX ) may be thrilled to learn that the covering analyst has just delivered a...

Athersys (ATHX) Q2 2022 Earnings Call Transcript
12 Aug, 2022 FinancialContent

ATHX earnings call for the period ending June 30, 2022.

Athersys needs to raise capital to survive, CEO says
11 Aug, 2022 Yahoo! Finance

In June, Athersys embarked on a financial and operational restructuring to lower its cost and conserve cash while commercialization its adult stem-cell therapy.

Recap: Athersys Q2 Earnings
11 Aug, 2022 FinancialContent

Athersys (NASDAQ:ATHX) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:00 PM. Here's what investors ...

Athersys Reports Second Quarter 2022 Financial Results and Provides Business Update
11 Aug, 2022 FinancialContent

Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three and six months ended June 30, 2022 and provided a business update.

Why Is CarLotz Higher By More Than 30%: Here Are 28 Stocks Moving Premarket
10 Aug, 2022 FinancialContent

Gainers ObsEva SA (NASDAQ: OBSV) shares rose 33.8% to $0.4080 in pre-market trading. ObsEva recently announced a $31 million debt ...

Radiation Countermeasure Study Data For U.S. Defense Department Gets First Readout
08 Aug, 2022 FinancialContent

Athersys Inc(NASDAQ: ATHX) hasannounced the resultsof a radiation countermeasure study that showed intravenous ...

Athersys Announces Favorable Preclinical Results for MultiStem® Treatment in Defense Department Radiation Countermeasure Study and Upcoming Webinar to Review Preclinical Research With MultiStem Across
08 Aug, 2022 FinancialContent

Athersys, Inc. (Nasdaq: ATHX) announces today results of a radiation countermeasure study conducted by the Armed Forces Radiobiology Research Institute (AFRRI), a Department of Defense research laboratory under the leadership of the Uniformed Services University of the Health Sciences, that showed intravenous MultiStem® (invimestrocel) administration provided benefit in an animal model of acute radiation syndrome (ARS). The results demonstrate that the administration of MultiStem cells increased survival in treated animals compared to vehicle treatment (p=0.03), resulted in higher body weights in surviving animals and positive trends in recovery of the hematopoietic system.

Athersys Announces Favorable Preclinical Results for MultiStem® Treatment in Defense Department Radiation Countermeasure Study and Upcoming Webinar to Review Preclinical Research With MultiStem Across Multiple Indications
08 Aug, 2022 Yahoo! Finance

CLEVELAND, August 08, 2022--Athersys, Inc. (Nasdaq: ATHX) announces today results of a radiation countermeasure study conducted by the Armed Forces Radiobiology Research Institute (AFRRI), a Department of Defense research laboratory under the leadership of the Uniformed Services University of the Health Sciences, that showed intravenous MultiStem® (invimestrocel) administration provided benefit in an animal model of acute radiation syndrome (ARS). The results demonstrate that the administration

Athersys hires turnaround consultant as interim CFO
04 Aug, 2022 Yahoo! Finance

Athersys Inc., the Cleveland-based regenerative medicine company, has hired turnaround specialist Ankura Consulting Group LLC and appointed the firm's senior managing director, Kasey Rosado, as its interim chief financial officer. Athersys lost its previous CFO, Ivor Macleod, in June through a restructuring — which included cutting its workforce by as much as 70% — aimed at reducing costs and making it an attractive investment for potential financial or strategic partners. New York-based Ankura offers management consulting and expert services "at critical inflection points," including corporate restructuring, bankruptcy, dispute and litigation, according to its LinkedIn page.

Athersys Appoints Kasey Rosado as Interim Chief Financial Officer
04 Aug, 2022 FinancialContent

Athersys Appoints Kasey Rosado as Interim Chief Financial Officer - Brings Operational Excellence and Financial Experience to Leadership Team

Athersys shareholders vote to approve reverse stock split
02 Aug, 2022 Yahoo! Finance

Athersys leaders want to consolidate the company's shares to raise their trading price and increase the number of shares that could be issued in the future.

Why Celyad Oncology Is Trading Higher By Over 31%; Here Are 29 Stocks Moving Premarket
01 Aug, 2022 FinancialContent

Gainers MAIA Biotechnology, Inc. (NASDAQ: MAIA) rose 37.9% to $8.00 in pre-market trading after jumping 30% on Friday. The company ...

This Communication Services Stock Jumped 149%; Here Are 90 Biggest Movers From Friday
01 Aug, 2022 FinancialContent

Gainers Getty Images Holdings, Inc. (NYSE: GETY) shares climbed 149.1% to close at $26.15 on Friday following its merger with ...

12 Health Care Stocks Moving In Friday's Intraday Session
29 Jul, 2022 FinancialContent

Gainers NRX Pharmaceuticals (NASDAQ:NRXP) stock increased by 72.0% to $0.9 during Friday's regular session. As of ...

Why Lottery.com Shares Are Trading Lower By 59%? 54 Stocks Moving In Friday's Mid-Day Session
29 Jul, 2022 FinancialContent

Gainers Getty Images Holdings, Inc. (NYSE: GETY) shares jumped 106.7% to $21.69 after nearly 99.4% of shares were redeemed by ...

This Healthcare Stock Tumbled 43%; Here Are 88 Biggest Movers From Yesterday
29 Jul, 2022 FinancialContent

Gainers Athersys, Inc. (NASDAQ: ATHX) climbed 71.1% to close at $0.3250 on Thursday after gaining 10% on Wednesday. Athersys is ...

12 Health Care Stocks Moving In Thursday's Intraday Session
28 Jul, 2022 FinancialContent

Gainers Athersys (NASDAQ:ATHX) stock rose 73.2% to $0.33 during Thursday's regular session. The current volume of ...

Why Shares of Solar Companies Are Trading Higher? 64 Stocks Moving In Thursday's Mid-Day Session
28 Jul, 2022 FinancialContent

Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) gained 231% to $2.63 on news that the company will be acquired By Henry Crown ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session
28 Jul, 2022 FinancialContent

Gainers Better Therapeutics (NASDAQ:BTTX) shares moved upwards by 67.3% to $2.56 during Thursday's pre-market ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
28 Jul, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! It's time for another dive into the biggest pre-market stock movers as we check out what's happening Thursday morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” Cash Holders Could Get Hit Hard THIS FRIDAY

Why Meta Platforms Is Trading Lower By More Than 6%: Here Are 34 Stocks Moving Premarket
28 Jul, 2022 FinancialContent

Gainers JAKKS Pacific, Inc. (NASDAQ: JAKK) rose 34.7% to $23.01 in pre-market trading after the company reported ...

Athersys to Host Second Quarter Financial Results Call
26 Jul, 2022 FinancialContent

Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2022 financial results at approximately 4:00 PM Eastern Time on Thursday, August 11, 2022, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results.

Athersys loses $100M stock purchase agreement with Aspire Capital
08 Jul, 2022 Yahoo! Finance

The biotechnology investment fund had the right to terminate the purchase agreement after Athersys laid off three top executives during a restructuring last month.

The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug
08 Jul, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pfizer, Africa CDC Strikes ...

Athersys and Aspire Capital Fund Terminate Relationship
08 Jul, 2022 FinancialContent

Athersys, Inc. (Nasdaq: ATHX) today announced that its equity purchase agreement with Aspire Capital Fund LLC (Aspire Capital) has been terminated. The Company continues to evaluate alternative financing options to support continuing operations. After several discussions with Aspire Capital, Athersys received notice on July 6, 2022 of termination of the equity purchase agreement, effective immediately. The equity purchase agreement had been in place since May 12, 2022.

Thinking about buying stock in Cowen, OneConnect Financial Tech, Faraday Future Intelligent Electric, RA Medical Systems, or Athersys?
05 Jul, 2022 Yahoo! Finance

InvestorsObserver issues critical PriceWatch Alerts for COWN, OCFT, FFIE, RMED, and ATHX.

This Healthcare Stock Surges Around 115%, Here's 74 Biggest Movers From Yesterday
30 Jun, 2022 FinancialContent

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) shares surged 114.3% to close at $0.2550 on Wednesday after the company ...

Athersys, Inc (ATHX) is a NASDAQ Common Stock listed in , ,

970x250